|
Cytogenetically normal acute myeloid leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Consolidation chemotherapy alone may overcome higher relapse rates by reducing the treatment mortality and increasing survival after relapse events in patients with CEBPA (dm) in NK-AML.
|
26537612 |
2016 |
|
Cytogenetically normal acute myeloid leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Diagnostic testing for CEBPA mutations is the standard of care for cytogenetically normal acute myeloid leukemia.
|
25468431 |
2015 |
|
Cytogenetically normal acute myeloid leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
CEBPA copy number variations in normal karyotype acute myeloid leukemia: Possible role of breakpoint-associated microhomology and chromatin status in CEBPA mutagenesis.
|
26460249 |
2015 |
|
Cytogenetically normal acute myeloid leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Altogether, our data provide a potential explanation for the improved clinical outcomes observed in CEBPA-mutated CN-AML patients, and suggest that lenalidomide treatment enhancing the C/EBPα-p30 protein levels and in turn miR-181a may sensitize AML blasts to chemotherapy.
|
23100311 |
2013 |
|
Cytogenetically normal acute myeloid leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Cytogenetically normal acute myeloid leukemia (CN-AML) with biallelic CEBPA gene mutations (biCEPBA) represents a distinct disease entity with a favorable clinical outcome.
|
22649106 |
2012 |
|
Cytogenetically normal acute myeloid leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Molecular evaluation of CEBPA gene mutation in normal karyotype acute myeloid leukemia: a comparison of two methods and report of novel CEBPA mutations from Indian acute myeloid leukemia patients.
|
22731647 |
2012 |
|
Cytogenetically normal acute myeloid leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Monoallelic CEBPA mutations in normal karyotype acute myeloid leukemia: independent favorable prognostic factor within NPM1 mutated patients.
|
22362118 |
2012 |
|
Cytogenetically normal acute myeloid leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We evaluated concurrent gene mutations, clinical outcome, and gene expression signatures of CCAAT/enhancer binding protein alpha (CEBPA) double mutations (CEBPA(dm)) versus single mutations (CEBPA(sm)) in 1182 cytogenetically normal acute myeloid leukemia (AML) patients (16-60 years of age).
|
21177436 |
2011 |
|
Cytogenetically normal acute myeloid leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Markers such as mutations in nucleophosmin 1 gene and CCAAT/enhancer binding protein alpha gene have been associated with a more favorable prognosis in CN-AML.
|
21522052 |
2011 |
|
Cytogenetically normal acute myeloid leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
CEBPA-mutated normal karyotype acute myeloid leukemia (AML) has recently been included as a provisional entity in the World Health Organization classification.
|
20888888 |
2011 |
|
Cytogenetically normal acute myeloid leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To integrate available clinical and molecular information for cytogenetically normal acute myeloid leukemia (CN-AML) patients into one risk score, 275 CN-AML patients from multicenter treatment trials AML SHG Hannover 0199 and 0295 and 131 patients from HOVON/SAKK protocols as external controls were evaluated for mutations/polymorphisms in NPM1, FLT3, CEBPA, MLL, NRAS, IDH1/2, and WT1.
|
21372155 |
2011 |
|
Cytogenetically normal acute myeloid leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
TET2 mutations were not associated with outcomes in the ELN intermediate-I-risk group (CN-AML with wild-type CEBPA and wild-type NPM1 and/or FLT3-ITD).
|
21343549 |
2011 |
|
Cytogenetically normal acute myeloid leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Prognostic significance of the BAALC isoform pattern and CEBPA mutations in pediatric acute myeloid leukemia with normal karyotype: a study by the Japanese Childhood AML Cooperative Study Group.
|
20495894 |
2010 |
|
Cytogenetically normal acute myeloid leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mutations occur in several genes in cytogenetically normal acute myeloid leukemia (AML) cells: the nucleophosmin gene (NPM1), the fms-related tyrosine kinase 3 gene (FLT3), the CCAAT/enhancer binding protein alpha gene (CEPBA), the myeloid-lymphoid or mixed-lineage leukemia gene (MLL), and the neuroblastoma RAS viral oncogene homolog (NRAS).
|
18450602 |
2008 |
|
Cytogenetically normal acute myeloid leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
349 CN-AML samples were subsequently screened for CEBPA mutations by fragment length analysis.
|
18752591 |
2008 |
|
Cytogenetically normal acute myeloid leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recent insights have allowed normal karyotype acute myeloid leukemia (AML) to be split into many molecular entities according to the genetic status of FLT3, NPM, CEBPA and MLL.
|
18452069 |
2008 |
|
Cytogenetically normal acute myeloid leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study.
|
18809607 |
2008 |